<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(6)</volume><submitter>Jiang T</submitter><journal>Translational lung cancer research</journal><pagination>2514-2517</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7815344</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Osimertinib in combination with bevacizumab in &lt;i>EGFR&lt;/i>-Mutated NSCLC with leptomeningeal metastases.</pubmed_title><pmcid>PMC7815344</pmcid><pubmed_authors>Hu J</pubmed_authors><pubmed_authors>Zhou C</pubmed_authors><pubmed_authors>Ding N</pubmed_authors><pubmed_authors>Jiang T</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Xu X</pubmed_authors><pubmed_authors>Hu Q</pubmed_authors></additional><is_claimable>false</is_claimable><name>Osimertinib in combination with bevacizumab in &lt;i>EGFR&lt;/i>-Mutated NSCLC with leptomeningeal metastases.</name><description/><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Dec</publication><modification>2025-04-05T14:48:03.754Z</modification><creation>2025-02-19T01:41:15.694Z</creation></dates><accession>S-EPMC7815344</accession><cross_references><pubmed>33489813</pubmed><doi>10.21037/tlcr-20-984</doi></cross_references></HashMap>